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Summary: The therapeutic potentials of probiotics in autism spectrum disorder (ASD) remains 
controversial, with the only existing systematic review on this topic published in 2015. Results 
from new trials have become available in recent years, we therefore conducted an updated 
systematic review, to assess the efficacy of probiotics in relieving behavioral symptoms of ASD 
and gastrointestinal comorbidities. Our review includes two randomized controlled trials, which 
showed improvement of ASD behaviors, and three open trials, all which exhibited a trend of 
improvement. Four of these trials concluded from subjective measures that gastrointestinal 
function indices showed a trend of improvement with probiotic therapy. Additional rigorous 
trials are needed to evaluate the effects of probiotic supplements in ASD.  
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      Autism spectrum disorder (ASD) is a complex neurological and developmental disorder 
characterized by impaired communication and social interaction skills, as well as stereotypical 
repetitive behavioral patterns[1]. The prevalence of ASD has more than doubled from 1 in 150 as 
of 2000 to 1 in 59 as of 2018 in the United States of America[1], with a similar trend world-wide[2, 
3]. Its etiology remains elusive, and it is thought to involve a combination of genetic changes and 
environmental factors[4, 5]. Among these pathogenic factors, microbiome dysbiosis of the 
gastrointestinal (GI) system appears to be an important player[6, 7]. In ASD patients, GI 
symptoms are more prevalent than their neurotypical counterparts[8, 9]. The degree of GI 
dysfunction is closely associated with alterations of gut microbiome, including changes in 
quantity, diversity, and enrichment or deficiency of certain taxonomic groups[8, 10]. Further, the 
severities of neurological and behavioral symptom in ASD correlate with gut microbiome 
profiles in some subgroups of patients[8, 10, 11]. These findings highlight the exciting possibility 
that microbiome manipulation may be an attractive target for therapeutic interventions for ASD. 
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       Current management strategies for ASD focus on behavioral therapies, psychiatric 
medications and specific treatments for individual comorbidities, all with limited success. 
Parents, clinicians and scientists have explored alternative therapies, including strategies to 
modify gut microbiome[12, 13]. These include prebiotics, probiotics, antibiotics, special diets, fecal 
microbial transplantation and even helminth therapies[11, 12, 14, 15].  
       Probiotic supplementation is one of the most popular approaches due to ease of use, wide 
availability and good safety profiles. Probiotics are a concoction of living microbial strains that 
are ingested and believed to colonize the gut to benefit host health. One Escherichia coli strain, 
several lactic acid producing Lactobacillus strains, and a number of Bifidobacteria comprise the 
primary microorganisms classified as probiotic strains[11, 14, 16]. It has emerged as an emerging 
adjunctive therapy for several inflammatory conditions, such as inflammatory bowel disease[17] 
and antibiotics associated diarrhea[18]. Probiotics may aid in ASD rehabilitation by promoting 
leaky gut healing, modulating neuronal functions via a vagus nerve-mediated “gut-brain axis”, or 
reducing inflammation of the central nervous system by bacterial metabolites[11, 14, 19, 20].  
          However, the therapeutic potentials of probiotics in ASD is still inconclusive[16]. It is 
unclear whether and to what extent probiotics can alleviate patients’ GI symptoms, behavioral 
symptoms, or both. The formulation and dosage of probiotics, and suitable target ASD subtypes 
also remain poorly defined[16]. Despite promising murine studies showing direct evidence of 
behavioral modification after probiotic supplementation[21, 22], clinical correlates in human 
studies are less convincing. The current literature consists of mostly case reports, small scaled 
observational studies and cohort studies. Results in clinical trials are mixed, possibly due to the 
differences in species or strain of probiotic used, or methodological and population variations 
among the studies. High quality, large scale randomized controlled trials (RCTs) are lacking due 
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to ASD’s status as a vulnerable population.  
      The only existing and the most recent systematic review published in 2015 included 4 studies 
with mixed study designs (including one RCT) and did not address probiotics’ effect on ASD 
behaviors[16]. All recent review articles since 2015 are qualitative. In the past three years, a 
number of new studies have become available, which all focused on probiotic therapy’s effect on 
behavioral modifications. We therefore conducted an updated systematic review of clinical trials, 
including RCTs and non-randomized (or quasi-experimental) controlled trials (non-RCTs), to 
comprehensively assess the efficacy of probiotics in behavioral symptoms of ASD, and where 
possible, GI comorbidities, adverse effects, and other objective changes measured by biomarkers 
and stool microbiome compositions.  
1 MATERIALS AND METHODS 
    This systematic review/meta-analysis was performed and reported following the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S2 Table).  
1.1 Search Strategy and Study Selection  
     We conducted a medical literature search using PUBMED, EMBASE, ProQuest thesis 
database and US National Library of Medicine clinical trial registry up to January 2018. The 
eligibility criteria were defined a priori, which include (1) the study includes a probiotic 
intervention targeting ASD population; (2) the study includes neurobehavioral assessment before 
and after intervention (studies with GI-only outcome measures are excluded); (3) the study is a 
confirmed RCT or non-RCT. We also included unpublished but completed studies in the above 
categories for which authors granted the right to include in the present study. The following 
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types of articles are excluded: anecdotal case reports of single patients, case series and any other 
retrospective study designs, prospective observational studies, analysis of electronic medical 
record or registries databases, narrative review articles, commentaries, mechanism of action 
research articles, or meta-analysis or systematic reviews.  
       Studies in ASD were searched with the terms “autistic disorder”, “autism spectrum disorder”, 
or “autism”, as medical subject headings. The term “autism” or “asperger” were used as free text 
terms. These terms were combined using the set operator AND with articles searched with the 
following terms: “probiotics” or “probiotic”, “Saccharomyces”, “Lactobacillus”, 
“Bifidobacterium”, or “Escherichia coli”, both as medical subject heading terms and as free text 
items. We did not impose language restrictions. Titles and abstracts of the papers identified by 
this initial search strategy were evaluated by two independent reviewers (JL and MH). We 
obtained potentially relevant papers and conducted subsequent full text screen. We also 
conducted a recursive search of the literature based on the bibliographies of the relevant full text 
articles. Two independent reviewers conducted full text screen using pre-designed eligibility 
criteria. Any disagreement between investigators was resolved by consensus.  
1.2 Outcome Assessment  
1.2.1 ASD Behavioral Outcome(s)    The outcomes included improvements in behaviors, such as 
overall assessment, speech/language/communication, sociability, sensory/cognitive awareness, 
and health/physical/behavior disruptive behavior. All available psychiatric comorbidities such as 
anxiety, aggressive behavior, inattention and opposition/defiance, were also extracted. Data were 
available in the following formats: (1) ASD behavioral scores (total and subcategories), 
determined using validated clinician evaluation tools, such as Clinical Global Impression 
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Severity (CGI-S) and Clinical Global Impression Improvement (CGI-I) forms. Data were 
extracted as continuous variables (mean, standard deviation [SD], total sample size [N]), in the 
format of treatment vs. baseline or treatment vs. placebo control.  (2) ASD behavioral scores 
(total and subcategories), determined using validated parent/care-giver assessment questionnaires, 
such as the Autism Treatment Evaluation Checklist (ATEC), Development Behavior Checklist– 
primary caregiver version(DBC-P), Aberrant Behavior Checklist-Taiwan version (ABC-T), 
Child Behavior Checklist (CBCL), Social Responsiveness Scale (SRS), and Swanson, Nolan and 
Pelham Questionnaire-IV-Taiwan version (SNAP-IV-T) questionnaires. Data were extracted as 
continuous variables (mean, SD, N), in the format of treatment vs. baseline or treatment vs. 
placebo control. (3) Patient improvement in ASD behavioral scores, data were extracted as 
dichotomous variables (either as number of patients who showed improvement/number of 
patients who did not show improvement; or as percentage of patients who showed improvement 
and N), in the format of treatment vs. baseline or treatment vs. placebo. 
1.2.2 ASD GI Function Outcome(s)     Data for the following GI symptoms/problems were 
extracted from the included articles: overall assessment, constipation, diarrhea, stool consistency, 
stool smell, flatulence, flatus, abdominal pain, stool frequency, wherever available. Data were 
available in the following formats: (1) GI function scores (total and subcategories), determined 
using validated tools such as GSI (GI severity index) or ATEC subcategory. Data were extracted 
as continuous variables (mean, SD, N), in the format of treatment vs. baseline or treatment vs. 
placebo control. (2) Patient improvement in GI scores (as above) or GI symptoms according to 
qualitative GI diary or stool card. Data were extracted as dichotomous variables (either as 
number of patients who showed improvement/number of patients who did not show 
improvement; or as percentage of patients who showed improvement and N), in the format of 
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treatment vs. baseline or treatment vs. placebo. 
    In addition, we collected information on other outcomes, including other adverse events, study 
withdrawals, including all-cause withdrawals and withdrawals from adverse events, as well as 
serum or stool biomarker changes, if available.  
1.3 Data Extraction  
    One reviewer extracted data from each study into a pre-piloted Microsoft Excel spreadsheet 
(XP professional edition; Microsoft Corp, Redmond, WA, USA). A second reviewer cross-
checked each data variable extracted against the original publication. Disagreement was resolved 
via discussion. In addition, the following information was extracted wherever available 
(including RCT, non-RCTs): age of trial participants, gender of trial participants, country of 
origin, setting of the study (primary, secondary or tertiary care-based), probiotic species, dosage 
and schedule of probiotics, dosage and schedule of control therapy if applicable, duration of 
therapy, number of individuals incurring any adverse events. When necessary, we contacted the 
authors to obtain original data via e-mail. Authors of Parrachoet al[13], Kałużna-Czaplińska et 
al[23], and West et al[24] were contacted but no additional original data was returned. 
1.4 Assessment of Risk of Bias  
    This was conducted by two investigators according to guidance published in the Cochrane 
Handbook[25]. For RCTs, risk of bias was assessed by recording the Cochrane Collaboration’s 
risk of bias method used to assess randomization generation, concealment of treatment allocation, 
and whether blinding was implemented for participants, personnel, and outcomes assessors 
(Table 1). We also examined evidence of incomplete outcomes data, and whether there was 





evidence of selective reporting of outcomes. Each domain was rated as low, unclear and high. 
For non-RCTs and before-and-after studies, level of evidence was graded based on the 
methodological index for non-randomized studies (MINORS) scale (Table 2)[26]. Study authors 
were contacted to obtain further information (e.g. details on blinding) if necessary. Risk of bias 
was assessed for each outcome. Any disagreement in risk of bias assessment was resolved by 
discussion. 
1.5 Qualitative Data Synthesis 
    Due to small number of studies, the variability in the assessment tools used and limited 
availability of data from included studies, we predominantly adopted qualitative approach for 
data synthesis. All relevant statistically significant changes, missing data, changes that are not 
significant or have no discussion of statistical significance, were reported and summarized in 
Tables 1, 2, and 4-6. 
2 RESULTS 
    Initial literature searches identified 1260 articles (fig. 1). Three additional papers were 
published and identified through hand-search of systematic review reference lists. We 
additionally identified 7 ongoing/recently completed studies including one published RCT 
protocol that met inclusion criteria. Authors of one of the recently completed studies gave 
permission to include their results in the present systematic review, but results are not available 
for the other studies. After removing duplicates, 727 articles were excluded based on title and 
abstract screening (162 further duplicates, 31 retrospective study design, 16 mechanism research, 
37 animal research, 6 analysis of clinical database or registries, 156 review articles, 190 not 





about ASD and/or probiotics, 3 case series, 6 case report, 7 study designs that satisfy the 
inclusion criteria but do not involve behavioral assessment, 8 book chapter, conference abstract, 
105 no abstract or full text available).  After title and abstract screening, 19 articles were selected 
for full-text screening. In total, 5 papers, including two RCTs and three non-RCTs, met inclusion 
criteria for the present systematic review and meta-analysis[13, 23, 24, 27, 28]. An overview of the 
reviewed studies is presented in Table 3. The other 14 articles were excluded (4 duplicates, 1 
RCT protocol only, 1 inappropriate patient population, 3 inappropriate study design, 3 
inappropriate outcomes, 1 inappropriate intervention, 1 review). Of the two RCTs, one was a 
randomized parallel double-blind placebo-controlled trial whereas one was a randomized double-
blind cross-over study. The other three studies were non-randomized, open-label, single arm, 
before-and-after interventional trials.  
2.1 Characteristics of Study Participants  
    As shown in tables 4 and 5, the two RCTs included a total of 142 patients (age range: 4-16 
years), all of whom were diagnosed with ASD. None of the studies included information 
regarding ASD subtypes. Approximately 98% were male and approximately 2% were female. 
        In comparison, three non-RCT studies included 85 patients with ASD (age range: 3–16 
years). Gender proportions cannot be calculated because one of the studies did not report 
patient gender. For the two studies where gender proportions are reported, 75% pooled total 
subjects were male and 25% were female. None of the studies included information 









2.2 Probiotics Used and Features of Treatment  
    The RCTs all studied the used of probiotics with a placebo comparator (table 6). Liu et al[27] 
 and Parrachoet al[13] both used Lactobacillus plantarum as intervention with similar dosage (3 
vs 4.5 x 10^10 CFU/capsule/D), and similar duration of treatment (4 vs 3 weeks), 
respectively. 
        Probiotic strains used in the open trials varied, including Lactobacillus acidophilus[23], a 
mixture of Lactobacillus acidophilus, Lactobacillus rhamnosus and Bifidobacterialongum[28], 
and a mixture of Lactocillus acidophilus, Lactobacillus casei, Lactobacillus delbruecki, 
Bifidobacterialongum and Bifidobacteriabifidum[24]. Interestingly, intervention in Shaaban et 
al[28]also contains prebiotic ingredients (carrot powder), whereas intervention in West et al[24] 
contained postbiotic derivatives from L rhamnosus V strain including peptidoglycan, muramyl 
peptides, and nucleotide-containing components or DNA motifs. The three studies had variable 
durations of therapy (2 to 6 months), with a variable range of dosages. In Shaaban et al, the 
cohort received behavioral therapy during probiotics administration. Although patients with use 
of psychiatric medications within the preceding 3 months were excluded, it was not clear 
whether they received additional medications for behavioral symptoms during the probiotics 
intervention. In Kałużna-Czaplińska et al[23], it is unclear whether patients received therapy or 
medication for ASD (author contacted, no reply). In West et al, 14.25% patients were receiving 
concurrent prescription medications, but the nature of the medications was not specified and 
there is no information regarding ongoing behavioral therapies (author contacted, replied but no 





2.3 Risk of Bias and Quality of Evidence 
    Tables 1 and 2 outline risk of bias and quality assessment ratings for each of the included 
studies. For RCTs, Liu et al[27] was deemed to have overall high quality of study design, and 
Parracho et al[13] is downgraded to moderate quality because of higher risks of bias. Open trials 
were mostly judged to be at serious to critical risk of bias, due to lack of randomization, blinding 
and control groups. Their results are at most indicators of clinical experience instead of evidence 
for the effectiveness of the intervention. Apart from Shaaban et al[28] methodological quality for 
these studies were graded as low to very low. Shaaban et al received moderate grade of quality 
rating due to its superior study design, including larger sample size, appropriate baseline 
characterizations, use of appropriate statistical methods assessment tools.  
2.4 Qualitative Data Synthesis  
2.4.1 Behavioral Modification    As shown in Table 4, the two RCTs used different tools to 
assess ASD behavioral symptoms. Parracho et al[13] used a care-giver questionnaire, DBC-P, 
which is a ranking score test consisting of 96 items. It assesses five major categories of 
behavioral characteristics including Disruptive/Antisocial behavior, Self-absorbedness, 
Communication disturbances, Anxiety, and Social Relating. Liu et al adopted both clinician 
assessment tools and care-giver questionnaires to evaluate ASD-related behavioral symptoms. 
They cover a more comprehensive range of psychiatric, behavioral and social symptoms of ASD. 
Lower score indicates less symptom in every test.  
      The two RCTs were unable to provide conclusive evidence for improvement of ASD 
behavior indices using either subjective or objective measurements, due to suboptimal statistical 
analysis methodologies used in both studies. Parracho et al[13] claimed statistically significant 
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improvement of behavioral scores for disruptive antisocial behavior, anxiety problems, and 
communication disturbances compared to baseline following probiotics treatment (p<0.05), with 
no simultaneous improvement in the placebo arm. Although the overall indicator of 
behavioral/emotional disturbances calculated by the total DBC-P score was lower (better) after 
treatment than baseline, the placebo group also showed improvement in this indicator from 
baseline. However, authors did not provide adequate statistical analysis between [end point-
baseline difference in placebo group] and [end point-baseline difference in treatment group], 
rending their analysis effectively that of an open trial. In Liu et al, no statistically significant 
differences in behavioral scores detected between probiotics and placebo control groups after 4 
weeks. Similar to Parracho et al, authors did not conduct statistical testing of the difference 
(score of week 4 – score of baseline) between PS128 (the strain L. plantarum used) and Placebo 
groups in the overall analysis.  
        In open trials, both West et al[24] and Shaaban et al[28] both used ATEC, whereas Kałużna-
Czaplińska et al[23] used an unspecified tool to assess ASD related behaviors. All three studies 
showed a trend of behavioral improvement with probiotics. All assessments were performed by 
care-givers. West et al showed mean ATEC score significantly decreased (p<0.05) following 
initiation of treatment, in all four of the ATEC categories including speech/language 
communication, sociability, sensory cognitive awareness, health/physical behavior. Shaaban et al 
showed that the total ATEC scores (p value=0.0001) and scores in all four categories (p<0.05) 
significantly decreased following probiotic supplementation. Kałużna-Czaplińska et al assessed 
patients’ ability of concentration, eye contact, follow out orders and reaction to other people’s 
emotions before and after treatment. They showed that a portion of the subjects showed 
improvement in each of the four domains of autistic behaviors, especially for “ability of 
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concentration” (60%) and “follow out orders” (68%). However, no statistical method was 
reported, and no concrete numbers or P values were attached to the proportions.  
2.4.2 GI Symptom Modification    Only one of the two RCTs, Parracho et al[13] assessed bowel 
functions (bowel movement and stool consistency) and GI symptoms (abdominal pain, intestinal 
bloating and flatulence) using a self-diary. Probiotic feeding resulted in a statistically significant 
(P<0.01) higher percentage of ‘formed’ stool (73.3%) compared to the placebo (64.8%), whilst 
the percentage of ‘hard’ stool samples was lower (8.1% vs 15.9%). On the other hand, no 
significant difference was detected for bowel movements and any GI symptoms between 
treatment and placebo groups compared to baseline.  
       All three open trials assessed GI function, to varying degrees, and all studies showed a trend 
of improvement of GI function indices using subjective measures. West et al[24] assessed GI 
function with both stool frequency diary and ATEC, which is completed by care-giver and has 
built-in assessment of constipation and diarrhea in the health/physical/behavior sub-category of 
the questionnaire. West et al showed the majority of participants in this study reported severe 
constipation (84%) or diarrhea (56%) at baseline; 48 % reported decreases in diarrhea severity 
and 52% reported decreases in constipation severity after treatment, although this is no 
discussion of statistical significance. Similarly, the study found reduction in ATEC-diarrhea (2.4 
vs 1.6) and constipation (1.0 vs 0.4) scores after treatment, but it is unclear whether the results 
are statistically significant. Parents also reported increased stool frequency although this was not 
statistically significant. Shaaban et al used modified six-item Gastrointestinal Severity Index (6-
GSI), another care-giver questionnaire including questions on constipation, diarrhea, stool 
consistency, stool smell, flatulence, and abdominal pain. Kałużna-Czaplińska et al[23] used an 
unspecified assessment tool. Shaaban et al[28] showed significant reduction in the total GSI score 
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(7.23 vs 3.57, p<0.0001), and in all sub-categories (p<0.05), including scores of constipation 
(1.27 vs 0.73), stool consistency (1.2 vs 0.87), flatulence (1.17 vs 0.87), and abdominal pain 
(1.17 vs 0.73) following probiotic supplementation. They also reported that 60% showed 
improvement in abdominal pain, 57% in flatulence, 42.5% in constipation, 37.5% in diarrhea, 25% 
in stool smell, and 16.6% in stool consistency. The author did not discuss statistical significance 
associated with the changes in proportions. Kałużna-Czaplińska et al[23] reported that 100% 
participants had GI symptoms at baseline. It did not report changes in GI function following 
treatment.  
2.4.3 Subgroup Analysis    Liu et al[27] is the only study that performed analysis by stratification. 
They divided the subjects treated with probiotics into ages of 7-12 and 13-15 years for 
questionnaire items that were identified as significantly different between treatment and baseline 
by the initial pooled analysis. The differences in scores (week 4 − baseline) for the 
questionnaires were examined. However, the subgroup analysis was done post-hoc (stratification 
was not described as part of the initial study design) and the authors did not comment on the 
statistical power for performing subgroup analysis.  
Liu et al’s post-hoc subgroup analysis showed a small but statistically significant 
improvement in SNAP-IV-T total score (P=0.02) and opposition/defiance sub-scale score 
(P=0.03) in probiotics groups. Difference (score of week 4 – score of baseline) between PS128 
and Placebo groups was compared by student’s t test[27]. 
2.4.4 Correlations between GI and behavioral symptoms improvement    Shaaban et al[28] shows 
improvements in gastrointestinal symptoms (assessed by the 6-GSI) were strongly correlated 
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with the improvements of the severity of autism (assessed by the ATEC) after probiotic 
supplementation, (r = 0. 674, p value= 0.0001). 
2.4.5 Adverse Effects  Overall, adverse effects of probiotic therapy are infrequent and non-severe, 
although only 40% included studies reported adverse effects. Only two studies reported adverse 
effects in detail. Shaaban et al monitored adverse effects throughout the study without providing 
details of assessment. No serious adverse effects were reported. In total 6 mild and transient 
incidences (out of N=30) were reported: diarrhea (1 patient), bloating (2 patients), abdominal 
cramps (2 patients) and skin rash (1 patient). Importantly, none of the patients reported cessation 
of the intervention. Parracho et al[13] is the only study that provided details on adverse effect 
monitoring (description of event, date and duration recorded throughout the study, on separate 
forms). They found that 4 subjects (out of N=62) withdrew from study due to adverse effects, 
including skin rash (1 patient), diarrhea (2 patients), and weight loss (1 patient).   
      Liu et al, West et al, and Kałużna-Czaplińska et al did not perform or performed only limited 
assessment of adverse effects. Liu et al included assessment of adverse effects though there was 
no detail on how this was done.  They reported diarrhea as the only adverse effect. However, it 
was not clear what proportion of patients experienced this adverse effect, and whether the 
proportion of subjects suffering from diarrhea differ in the treatment and placebo groups. West et 
al did not design their study to monitor adverse events, but authors noted that none of the 
respondents reported cessation of intervention due to adverse effects. There was no mentioning 
of adverse effect assessment in Kałużna-Czaplińska et al.  
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2.4.6 Changes in Stool/Urine Markers and Other Clinical Indices   Parracho et al[13] and Shaaban 
et al[28] assessed changes in the stool microbiota composition. Parracho et al found that probiotic 
supplementation resulted in significantly higher Lab158 (Lactobacilli and Enterococci group) 
counts, and significantly lower Erec482 (Clostridium cluster XIVa) compared to the placebo 
group. In Shaaban et al, the stool samples were tested to compare the levels of beneficial bacteria 
(mainly Bifidobacteria and Lactobacillus species) between patients with ASD and healthy 
controls (note: the study only included healthy controls for stool assessment and not for 
probiotics treatment). They found that the levels of Bifidobacteria were significantly lower in 
stool of ASD children compared to control group (p value=0.0001) at baseline. After probiotics 
treatment, there was a significant increase in the colony counts of Bifidobacteria and 
Lactobacillus in stool of autistic children using PCR method (p value <0.0001).  
       Shaaban et al also showed that (n=18) overweight patients had a statistically significant 
decrease in the body weight (p< 0.014) and BMI (p value < 0.01) after probiotic treatment for 3 
months.  
      Kałużna-Czaplińska et al[23] assessed the level of urine D-arabinitol (DA, a metabolite of 
pathogenic candida species shown to be elevated in urine of ASD patients) and the ratio of urine 
D-/L-arabinitolin the urine of children with autism before and after probiotic treatment using 
capillary gas chromatography/mass spectrometry. The probiotic supplementation let to a 
significant decrease in D-arabinitol and the D-/L-arabinitolratio (P<0.05) 
3 DISCUSSION 
    We conducted a systematic review to qualitatively synthesize the available evidence on the 
efficacy and safety of probiotic supplementation as an adjunctive treatment for ASD. In contrast 
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to the 2015 systematic review that included retrospective studies, we only included prospective 
RCTs and open-label trials in order to minimize bias, confounding, and difficulty making causal 
inferences. In summary, all studies (both RCT and non-RCTs) pointed towards a similar trend of 
improvement in both care-giver reported ASD symptoms and GI symptoms after probiotic 
therapies. Unfortunately, due to flaws in statistical analyses, the paucity of RCTs, inherent study 
limitations in non-randomized trials, and significant between-trial heterogeneity, our study 
provide only suggestive but not conclusive evidence regarding the efficacy of probiotics on GI 
and behavioral symptoms among ASD patients.  
3.1 Effect of Probiotics on ASD Symptoms: RCT Evidence 
    Among the two RCTs, Liu et al[27] offers superior study design, but both studies suffered from 
suboptimal statistical analysis. Although Parracho et al[13] designed their study as a placebo-
controlled trial, the authors only performed data analysis comparing baseline and post treatment 
behavioral scores without statistical analysis between delta value in the probiotics and placebo 
groups. Thus, the inadequate data analysis effectively rendered the study as an open-label trial, 
undermining the strength of their conclusion and rendering their claim of statistical significance 
invalid. Liu et al appeared to have made similar errors in their overall analysis, but they 
conducted statistical comparison of the difference (score of week 4 – score of baseline) between 
PS128 and Placebo groups in the subsequent subgroup analysis. 
        The effect sizes of behavioral improvement measured in both trials were small, if any, so 
the question remains whether such improvement should be considered clinically relevant. In 
addition, Liu et al[27] is the only study that adopted clinician assessment, yet it did not observe 
statistically significant ASD improvement using clinician assessment tools. Whereas Liu et al 
reported power calculation for determining sample sizes to assess anticipated effects on primary 
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outcomes, Parracho et al[13] did not include power calculation. Both trials also suffered from 
relatively short trial duration. Previous trials investigating the effect of probiotic therapies in 
inflammatory bowel diseases typically followed patients for 6-24 months of therapy[17]. Liu et al 
and Parracho et al both assessed the effect of the probiotics for less than 1 month. Since 
microbiome modification is a slow process and establishment of a new gut eco-system may take 
time, it is possible that the marginal clinical benefits observed in both studies can be partially 
attributable to the short durations of treatments. 
      Additionally, there are other factors that may contribute to between-trial inconsistencies, 
including small sample sizes, questionable allocation concealment/incomplete randomization, 
variable duration of treatments, high rates of dropouts (especially in Parracho et al), differences 
in the probiotic strains, and different study populations. Other issues that affect the quality of 
both studies include incomplete characterization of baseline characteristics, poorly defined 
primary and secondary end points, less comprehensive raw data reporting and adverse event 
reporting, and inadequate statistical modeling. Both RCTs observed very high levels of placebo 
effect, and Parracho et al noted high inter-subject variability.  
3.2 Effect of Probiotics on ASD Symptoms: Non-RCT Evidence 
    Non-RCT evidence was mostly consistent with the RCT results, which suggests that probiotics 
treatment may be beneficial in improving behavioral symptoms. However, these studies provide 
only lower quality evidence compared to RCTs due to potential for selection bias, confounding, 
or any residual sources of bias in the study design and statistical analysis. Among them, Shaaban 
et al appears to have higher-quality study design and lower risk of bias[28]. However, there may 
be serious flaws associated with their data analysis, which could further undermine their 
conclusion. For example, the author reported patients’ weight before and after probiotics 
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treatment to be 25.91 +/- 5.32 kg to 25.79 +/- 5.16 kg, respectively. This change was associated 
with a p-value of 0.014, which seems unlikely given the small sample size and small magnitude 
of change. We contacted the authors regarding this concern and requested original data, but 
authors did not reply to our inquiry. Therefore, it is not clear whether there are systematic errors 
associated with their data analysis related to other parts of the analysis, including primary 
outcomes. West et al carries the highest risk of bias and poorest study design and statistical 
methodology[24], whereas Kałużna-Czaplińskaet al had limited analysis of GI symptoms and 
behavioral symptoms despite having relatively low risk of bias[23]. 
3.3 Probiotics and GI Symptoms 
     Both RCT and non-RCT suggest that probiotics may improve GI symptoms, but high-quality 
evidence is lacking. Although most studies attempted to assess probiotics’ effect on GI 
symptoms, the majority of the trials were not adequately designed to do so. The study design of 
Parracho et al[13], West et al[24], and Shaaban et al[28] included children with GI symptoms as well 
as those without GI symptoms. However, none of the studies performed either stratification by 
GI symptoms initially or post-hoc subgroup analysis focusing on those with GI symptoms at 
baseline, which would be a more logical approach to assess probiotics’ effect on GI symptoms. 
Notably, neither of the two placebo-controlled trials were designed to assess GI symptoms. Liu 
et al did not assess GI symptoms, which is a major drawback of the study. Although Parracho et 
al compared GI scores between treatment and placebo group after the intervention, their analysis 
did not take into account the baseline GI symptoms. The inadequate statistical analysis seriously 
undermines their conclusion regarding GI symptom improvement.  
3.4 Adverse Effects of Probiotics  
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    Most studies were not designed to assess adverse reactions, including the only properly 
designed RCT, Liu et al[27] (Table 6). However, among the studies that monitored adverse effects, 
the reported adverse reactions appear to be mild and infrequent. Only Parracho et al[13] described 
study withdraw (4 out of 62) due to adverse effects.  
3.5 Dose-response Relationship  
    The five studies included in the current systematic review span a variety of treatment 
characteristics, including different probiotic strains, single vs multi-species, different treatment 
durations. Due to the paucity of data and poor inter-comparability between studies, there is 
currently no evidence to suggest that any treatment regimen is superior and whether single 
species is better than multiple species. In 3 out of the 5 studies examined, probiotics were used as 
an adjunctive therapy while patients continued to receive their regular medical management and 
behavioral therapies. Two studies did not specify medication and therapy use.  
       A probiotics dose-response relationship for treatment of GI symptoms and behavioral 
symptoms cannot be extrapolated based on the cumulative data from the existing trials due to the 
large heterogeneity between studies. According to recent meta-analyses, clinical studies 
investigating probiotic therapies for most other diseases such as Clostridium Difficile-associated 
diarrhea, necrotizing enterocolitis, prevention of atopic dermatitis, slow intestinal transit, 
prophylaxis in colorectal cancer and relief of irritable bowel syndrome, demonstrated no clear 
dose-response relationships[18]. On the other hand, both meta-analyses and dedicated dose-
response studies have observed a positive correlation between dose and antibiotic-associated 
diarrhea risk[18]. For inflammatory bowel disease, although most studies have not investigated 
dose-relationships[17] , one study examined several different doses of the probiotic and per 
protocol analysis indicated a statistically significant difference in dose-responsiveness; however, 
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they failed to show statistical significance in the intent-to-treat analysis[29]. In general, the dose 
concentration of probiotics needed to achieve clinical effect has been quoted as>106 cfu/ml in 
the small bowel and>108 cfu/g in the colon[30]. None of the studies included in this systematic 
review provided information regarding dose concentration. None of the studies included in this 
systematic review performed dose-response analysis. 
3.6 Differential Response to Probiotic by Subgroups of ASD Patients 
    ASD is a heterogeneous condition with tremendous individual variability and existing 
evidence is insufficient to reach any conclusion regarding which subgroup of patients may 
benefit the most from probiotics. The key question to parents, care-givers and clinicians is, if 
probiotic therapy works (which has yet to be proven by high quality RCTs), and what subtypes 
of ASD patients may benefit more from it.  Despite relatively insufficient power, sub-group 
analysis from this systematic review and meta-analysis suggest that ASD symptom improvement 
appeared to be associated with improvement of GI symptoms[28], and that the younger age group 
appeared to benefit more from probiotic therapy compared to older children[27]. There is 
insufficient data to compare treatment responses in different gender. Future studies may be able 
to show a greater impact of probiotics by limiting the cohorts to younger patients, and those with 
more severe baseline GI functions.  
3.7 Limitations  
    Limitations to this systematic review include the lack of robust empirical research on probiotic 
intervention for ASD in the published literature and hence small number of eligible studies. Even 
in studies that are included, most have small sample sizes that are not adequately powered, which 
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further limit the quality of this systematic review. The wide range of probiotic regimen together 
with the limited number of studies makes it unfeasible to compare effectiveness between studies 
using quantitative methods. In addition, there may be publication bias in this field, and clinical 
trials with only negative results may not have been published in the first place, therefore skewing 
the conclusion towards a more positive outlook of probiotic efficacy. 
3.8 Conclusion and Future Directions 
     Our systematic review of available trial data provided suggestive evidence regarding the 
potential beneficial role of microbiome dysbiosis in improving behavioral and GI symptoms 
among ASD patients. However, available RCTs and nonrandomized trials suffer from potential 
biases due to poorly designed trials with small sample sizes. Specifically, to promote 
comparability of future research, we call for ASD clinical investigators to standardize assessment 
tools for both behavioral symptoms and other symptoms of interest (e.g. using ATEC for ASD 
symptoms and GSI for GI functions). Due to the high placebo effect observed in the existing 
studies, it is also important for future research to consistently implement objective, clinician 
assessment rather than relying on care-giver report. Other tools, such as urine and serum markers, 
and stool microbiome (as done in Parrachoet al[13] and Shaaban et al[28]), can assist in the 
interpretation of the results. We noted that the majority of the current studies have not taken 
advantage of these tools. Several ongoing and new studies are in the horizon (S1 Table), and the 
field remains hopeful as more reliable data from rigorously designed RCTs become available in 
the near future. 
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1. Cochrane risk of bias assessment for RCTs. 
 





























   













































































































Liu 2018 Low Low Low Low High Low Unclear High 
Parracho 2010 Unclear Unclear Unclear High High Low Low Mod-erate 
 
2. MINORS risk of bias assessments for non-RCTs. 
 
MINORS Criteria for non-comparative/non-randomized studies  
 













































































































































































































































2017 Serious 2 2 2 2 1 2 2 0 NA NA NA 2 15/18 
Moderate 
Probiotic therapy for treating behavioral and gastrointestinal symptoms 




3. Basic characteristics of included studies. 
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4. Characteristics of probiotic therapies of included studies. 
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4.5x10^10 CFU  unclear 
Group I received 
placebo during 
the first feeding 
period (3 weeks) 
and probiotic 
during the second 
feeding period (3 
weeks) 
NA Maltodextrin, 110mg per capsule Not specified 





  3x10^10 CFU 1 capsule daily 4 weeks 
microcrystalline 
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5. Outcomes summary: ASD behaviors and GI symptoms. 
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Study 
ASD behaviors GI symptoms 
Assessment 
tool(s) Results Assessment tool(s) Results 
Parracho et 
al, 2010 [13] DBC-P 
1). Authors claimed statistically 
significant (p<0.05) improvement of 
behavioral scores for disruptive 
antisocial behavior, anxiety problems 
and communication disturbances, but 
data analysis is suboptimal (see results 
and discussion). 
Assessed bowel functions 
(bowel movement and stool 




flatulence) using a self-
diary. 
1). Authors claimed that probiotic feeding 
resulted in a statistically significant 
(P<0.01) higher percentage of ‘formed’ 
stool (73.3%) compared to the placebo 
(64.8%), whilst the percentage of ‘hard’ 
stool samples was lower (8.1% vs 15.9%), 
but data analysis is suboptimal (see results 
and discussion) 
2). No significant difference was detected 
for bowel movements and any GI symptoms 
between treatment and placebo groups 
compared to baseline. 










1). No statistically significant 
differences in behavioral scores detected 
between probiotics and placebo control 
groups after 4 weeks. Authors did not 
conduct statistical testing of the 
difference (score of week 4 – score of 
baseline) between PS128 and Placebo 
groups in the overall analysis.  
2). Post-hoc subgroup analysis showed a 
small but statistically significant 
improvement in SNAP-IV-T total score 
(P=0.02) and opposition/defiance sub-
scale score (P=0.03) in probiotics 
groups.  Difference (score of week 4 – 
score of baseline) between PS128 and 
Placebo groups was compared by 


















1). A portion of the subjects showed 
trend of improvement in each of the 
four domains of autistic behaviors, 
especially for “ability of concentration” 
(60%) and “follow out orders” 
(68%).(no P values)  
unspecified tool 
100% participants had GI symptoms at 
baseline. Authors did not report changes in 
GI function following treatment. 
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6. Other outcomes, adverse effects and comments. 
Study Adverse effects Other outcomes  comments 
Paraccho et al, 
2010 [13] 
4 subjects (out of N=62) 
withdrew from study due to 
adverse effects, including skin 
rash (1 patient), diarrhea (2 
patients), and weight loss (1 
patient),  
Probiotic supplementation resulted in 
significantly higher (p<0.05) Lab158 and 
significantly lower Erec482 counts compared 
to the placebo group.  
1). High dropout rate 
2). Didn't use ITT (intention -to-treat) analysis 
3). High inter-individual variability 
4). significant placebo effect 
5). Data analysis for primary outcome is inadequate  
Liu et al, 2018 
[27] 
Study included assessment of 
adverse effects though there 
was no detail on how this was 
done. Diarrhea was noted in 
some patients 
NA 
1). 2 authors are members of the company that 
develops the probiotic therapy 
2). Some analysis not ITT 
3). strong placebo effects 
4). No GI function assessment. 
West et al, 
2013 [24] ATEC score 
1). Mean ATEC score significantly 
decreased (p<0.05) following initiation 
of treatment, in all four of the ATEC 
categories including speech/language 
communication, sociability, sensory 
cognitive awareness, health/physical 
behavior. 
both stool frequency diary 
and ATEC, which has built-
in assessment of 
constipation and diarrhea 
1).The majority of participants in this study 
reported severe constipation (84%) or 
diarrhea (56%) at baseline; 48 % reported 
decreases in diarrhea severity and 52% 
reported decreases in constipation severity 
after treatment, although this is no 
discussion of statistical significance. 
2).Study found reduction in ATEC-diarrhea 
(2.4 vs 1.6) and constipation (1.0 vs 0.4) 
scores after treatment, but it is unclear 
whether the results are statistically 
significant. 3).Parents also reported 
increased stool frequency although this was 
not statistically significant. 
Shaaban et 
al, 2017 [28] ATEC score 
1). The total ATEC scores (p 
value=0.0001) and scores in all four 
categories (p<0.05) significantly 
decreased following probiotic 
supplementation. 
2). improvements in gastrointestinal 
symptoms were strongly correlated with 
the improvements of the severity of 
autism (assessed by the ATEC) after 




1). Significant reduction in the total GSI 
score (p<0.0001), and in all sub-categories 
(p<0.05), including constipation (1.27 vs 
0.73), stool consistency (1.2 vs 0.87), 
flatulence (1.17 vs 0.87), and abdominal 
pain (1.17 vs 0.73) with probiotics. 
2). 60% showed trend of improvement in 
abdominal pain, 57% in flatulence, 42.5% 
in constipation, 37.5% in diarrhea, 25% in 
stool smell, and 16.6% in stool consistency. 
(No P value) 
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5). No life style factors, microbiome changes, or 




Unclear whether adverse effect 
was assessed. None reported 
Probiotic supplementation let to a significant 
decrease in urine D-arabinitol and D-arabinitol 
/ L-arabinitol ratio (P<0.05) 
1). Poor overall statistical reporting 
2). Assessment tools unspecified 
3). Study did not track GI symptom changes after 
treatment 
West et al, 
2013 [24] 
Study was not designed to 
monitor adverse events NA 
1). 2 authors are members of the company that 
develops Delpro 
2). Poor statistical methods and no P values 
provided for changes in GI symptoms/ATEC-GI 
scores after treatment 
Shaaban et al, 
2017 [28] 
1). Side effects include 
diarrhea (1), bloating (2), 
abdominal cramps (2) and skin 
rash (1).  
2). All adverse effects were 
mild and transient, no patients 
reported cessation of the 
intervention. 
1) The levels of Bifidobacteria were 
significantly lower in stool of ASD children 
compared to healthy control group (p 
value=0.0001) at baseline. After probiotics 
treatment, there was a significant increase in 
the colony counts of Bifidobacteria and 
Lactobacillus (p value <0.0001). 
2) overweight ASD patients showed a 
statistically significant decrease in the body 
weight (p value < 0.014) with a significant 
decrease in BMI (p value < 0.01) after 
probiotic treatment.  
1). No financial conflict of interest 
2). P values and SDs are provided for each 
measurement 
3). important limitation is that cohort received 
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S1 Table. Ongoing clinical trials not included in this review. 
This table contains the characteristics of ongoing or completed but unpublished clinical trials that 
are researching the interaction of probiotics with Autism Spectrum Disorder symptoms and 
behavior.  
File Format: Microsoft Word Document 
 
S2 Table. PRISMA checklist 
This table contains the specifications of a review following the PRISMA guidelines, as this 
manuscript followed. PRISMA is a minimum list of items that must be completed when 
undergoing a review or meta-analysis and is a tool to evaluate these reviews.     
File Format: Microsoft Word Document 
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